Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Equillium sees cash, investments funding operations for at least next 12 months  16:03
05/12/22
05/12
16:03
05/12/22
16:03
EQ

Equillium

$2.20 /

-0.06 (-2.65%)

 
ShowHide Related Items >><<
EQ Equillium
$2.20 /

-0.06 (-2.65%)

EQ Equillium
$2.20 /

-0.06 (-2.65%)

03/24/22 H.C. Wainwright
Equillium price target raised to $15 from $12 at H.C. Wainwright
02/16/22 Stifel
Equillium's Bioniz acquisition bolsters itolizumab, says Stifel
01/12/22 Stifel
Equillium 'could be upside biased' into lupus nephritis data, says Stifel
10/29/21 Stifel
Equillium resumed with a Buy at Stifel
EQ Equillium
$2.20 /

-0.06 (-2.65%)

Earnings
Equillium reports Q1 EPS ($1.17), consensus (37c) » 16:02
05/12/22
05/12
16:02
05/12/22
16:02
EQ

Equillium

$2.20 /

-0.06 (-2.65%)

It's been a…

It's been a transformative start to the year, leading to significant enhancements in how we are building value going forward," said Bruce Steel, CEO at Equillium. "Since the beginning of the year we announced the acquisition of Bioniz Therapeutics, adding two first-in-class therapeutic candidates to our pipeline and an underlying novel drug discovery platform. This enables us to further expand our approach to business development and partnering efforts and significantly adds to our future operational milestones and pending data catalysts. In March we also announced the initiation of our Phase 3 EQUATOR study of itolizumab in first-line acute graft-versus-host disease and look forward to interim data from the Phase 1b EQUALISE study of itolizumab in patients with lupus nephritis expected mid-year."

ShowHide Related Items >><<
EQ Equillium
$2.20 /

-0.06 (-2.65%)

EQ Equillium
$2.20 /

-0.06 (-2.65%)

03/24/22 H.C. Wainwright
Equillium price target raised to $15 from $12 at H.C. Wainwright
02/16/22 Stifel
Equillium's Bioniz acquisition bolsters itolizumab, says Stifel
01/12/22 Stifel
Equillium 'could be upside biased' into lupus nephritis data, says Stifel
10/29/21 Stifel
Equillium resumed with a Buy at Stifel
EQ Equillium
$2.20 /

-0.06 (-2.65%)

Hot Stocks
Equillium: EHA publishes abstract on Phase 3 EQUATOR study » 08:22
05/12/22
05/12
08:22
05/12/22
08:22
EQ

Equillium

$2.18 /

-0.1 (-4.39%)

Equillium announced that…

Equillium announced that the European Hematology Association EHA has published an abstract highlighting the Phase 3 EQUATOR study in first-line acute graft-versus-host disease aGVHD. The abstract discusses acute graft-versus-host disease aGVHD being a major cause of morbidity and mortality following allogeneic hematopoietic stem cell transplant allo-HSCT and that there is no approved first-line treatment, where corticosteroids remain standard of care. Itolizumab, a humanized IgG1 monoclonal antibody that binds CD6 and blocks interaction with activated leukocyte cell adhesion molecule ALCAM to inhibit T effector cell activity and trafficking to target organs, represents a promising therapeutic approach to treat aGVHD, as suggested by safety and efficacy results from the Phase 1b EQUATE study. These results and benefit-risk profile led to the currently enrolling Phase 3 EQUATOR study, a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of itolizumab in combination with corticosteroids for the treatment of first-line aGVHD.

ShowHide Related Items >><<
EQ Equillium
$2.18 /

-0.1 (-4.39%)

EQ Equillium
$2.18 /

-0.1 (-4.39%)

03/24/22 H.C. Wainwright
Equillium price target raised to $15 from $12 at H.C. Wainwright
02/16/22 Stifel
Equillium's Bioniz acquisition bolsters itolizumab, says Stifel
01/12/22 Stifel
Equillium 'could be upside biased' into lupus nephritis data, says Stifel
10/29/21 Stifel
Equillium resumed with a Buy at Stifel
EQ Equillium
$2.18 /

-0.1 (-4.39%)

Hot Stocks
Equillium announces three poster presentations at IMMUNOLOGY2022 » 08:20
05/09/22
05/09
08:20
05/09/22
08:20
EQ

Equillium

$2.53 /

-0.06 (-2.32%)

Equillium announced that…

Equillium announced that three posters were presented over the weekend at IMMUNOLOGY2022, the annual meeting of The American Association of Immunologists. The meetings are taking place at the Oregon Convention Center in Portland, Oregon, May 6 - 10, 2022. Itolizumab is a first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway, which plays a central role in modulating both the activity and trafficking of the pathogenic T cells driving a number of immuno-inflammatory diseases. Details of Itolizumab Data Presented Title: CD6 - a costimulatory receptor at the nexus of Teff / Treg development: Key Highlights, Summary and Conclusions from Presentation: First study to directly characterize the role of CD6 in the development and activity of T regulatory cells. T regulatory cells derived from CD6 low cells had greater co-expression of FOXP3 and HELIOS vs. T regulatory cells derived from isotype-treated CD6 high cells. T regulatory cells possessed greater suppressive function, with an increase of at least 50% greater inhibition of proliferation and cytokine release by T responder cells than T regulatory cells derived from CD6 high cells. CD6 low T regulatory cells were able to suppress T responder cell production of pro-inflammatory cytokines by 60% - 90% compared to CD6 high T regulatory cells. Data suggests that reduced levels of cell surface CD6 facilitate the development of T regulatory cells with greater stability and suppressive activity, and that modulating the levels of CD6 may increase the T regulatory to T effector cell ratio in patients with autoimmune and inflammatory diseases. Title: Modulating levels of cell surface CD6 is a novel mechanism for regulating T cell activity. Key Highlights, Summary and Conclusions from Presentation: CD6 high cells are highly pathogenic and levels of CD6 have been implicated in numerous autoimmune and inflammatory diseases including multiple sclerosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, and acute graft-versus-host disease. Itolizumab-induced CD6 cleavage from the surface of T cells occurs through a transcellular event between a CD6 positive T cell and a CD14 positive monocyte. This cleavage event is mediated by functional Fc receptor binding of itolizumab to FcgammaRI. The loss of the extracellular domains of CD6 from the surface results in T cells that are hyporesponsive and less alloreactive to T cell stimulation. These results further support targeting CD6 as an effective means to inhibit pathogenic T cell activity in the treatment of autoimmune and inflammatory diseases as CD6 cleavage results in prolonged modulation of T cell activity. Title: The CD6-ALCAM pathway selectively modulates pathogenic T cell migration. Key Highlights, Summary and Conclusions from Presentation: CD4 positive and CD8 positive T cells that migrate in response to CXCL12, express higher levels of CD6 and that the amount of migration correlates with levels of CD6 expression, suggesting that CD6 is engaged during T cell migration across the endothelial monolayer. Decreasing CD6 expression led to decreased migration of effector memory T cells and terminally differentiated effector memory T cells while migration of T regulatory cells was unaffected, thus suggesting that targeting CD6 in autoimmune and inflammatory diseases would decrease infiltration of pathogenic T cells while still permitting modulation of the immune response by T regulatory cells. Th17 cells were stained from the total peripheral blood mononuclear cells population that migrated in response to CXCL12. Data showed a reduction of the migration of those cells after blocking the CD6-ALCAM pathway with itolizumab. This data suggests that CD6-ALCAM pathway is involved in the movement of T cells through the endothelial tissues and confirms CD6 as a target to prevent pathogenic T cell recruitment into inflamed organs.

ShowHide Related Items >><<
EQ Equillium
$2.53 /

-0.06 (-2.32%)

EQ Equillium
$2.53 /

-0.06 (-2.32%)

03/24/22 H.C. Wainwright
Equillium price target raised to $15 from $12 at H.C. Wainwright
02/16/22 Stifel
Equillium's Bioniz acquisition bolsters itolizumab, says Stifel
01/12/22 Stifel
Equillium 'could be upside biased' into lupus nephritis data, says Stifel
10/29/21 Stifel
Equillium resumed with a Buy at Stifel
EQ Equillium
$2.53 /

-0.06 (-2.32%)

Over a quarter ago
Conference/Events
Canaccord Genuity to hold a virtual conference » 04:55
03/29/22
03/29
04:55
03/29/22
04:55
ABST

Absolute Software

$8.34 /

-0.06 (-0.71%)

, AIF

Acceptance Insurance Group

$13.92 /

+0.005 (+0.04%)

, AT

Atlantic Power

$3.03 /

+ (+0.00%)

, BLD

TopBuild

$192.69 /

+1.685 (+0.88%)

, CLS

Celestica

$12.17 /

-0.1 (-0.81%)

, CTS

CTS Corporation

$35.60 /

-0.55 (-1.52%)

, CVO

Taken private

/

+

, DCBO

Docebo

$49.33 /

+0.66 (+1.36%)

, DOC

Physicians Realty Trust

$17.92 /

+0.29 (+1.64%)

, DSG

Diamond S Shipping

/

+

, ECOM

ChannelAdvisor

$16.42 /

+0.57 (+3.60%)

, EQ

Equillium

$3.01 /

-0.265 (-8.09%)

, FORA

Forian

$6.48 /

+0.34 (+5.54%)

, PVT

Pivotal Acquisition

/

+

, QFOR

Quadrant 4 System

/

+

, REAL

RealReal

$7.85 /

-0.01 (-0.13%)

Tech 2022: Themes in a…

Tech 2022: Themes in a Stock Picker's Market to be held on March 29.Webcast Link

ShowHide Related Items >><<
REAL RealReal
$7.85 /

-0.01 (-0.13%)

FORA Forian
$6.48 /

+0.34 (+5.54%)

EQ Equillium
$3.01 /

-0.265 (-8.09%)

DOC Physicians Realty Trust
$17.92 /

+0.29 (+1.64%)

DCBO Docebo
$49.33 /

+0.66 (+1.36%)

CTS CTS Corporation
$35.60 /

-0.55 (-1.52%)

CLS Celestica
$12.17 /

-0.1 (-0.81%)

BLD TopBuild
$192.69 /

+1.685 (+0.88%)

ABST Absolute Software
$8.34 /

-0.06 (-0.71%)

ABST Absolute Software
$8.34 /

-0.06 (-0.71%)

02/09/22 BMO Capital
Absolute Software price target lowered to C$14 from C$18.50 at BMO Capital
02/09/22 TD Securities
TD Securities upgrades Absolute Software to Buy after 'another' beat and raise
02/09/22 TD Securities
Absolute Software upgraded to Buy from Hold at TD Securities
08/11/21 BMO Capital
Absolute Software price target lowered to C$18.50 from C$20 at BMO Capital
AIF Acceptance Insurance Group
$13.92 /

+0.005 (+0.04%)

AT Atlantic Power
$3.03 /

+ (+0.00%)

BLD TopBuild
$192.69 /

+1.685 (+0.88%)

01/19/22 KeyBanc
TopBuild downgraded to Sector Weight from Overweight at KeyBanc
12/23/21
Fly Intel: Top five analyst upgrades
12/23/21 Zelman
TopBuild upgraded to Buy from Hold at Zelman
12/03/21
Fly Intel: Top five analyst downgrades
CLS Celestica
$12.17 /

-0.1 (-0.81%)

01/28/22 Canaccord
Celestica price target raised to $13.50 from $12 at Canaccord
09/23/21 Citi
Celestica price target raised to $8.50 from $8 at Citi
05/25/21 Stifel
Plexus warning may be signal that supply constraints will worsen, says Stifel
CTS CTS Corporation
$35.60 /

-0.55 (-1.52%)

01/31/22 Sidoti
CTS Corporation upgraded to Buy from Neutral at Sidoti
10/14/21 Cowen
CTS downgraded to Market Perform amid rising input costs at Cowen
10/14/21 Cowen
CTS Corporation downgraded to Market Perform from Outperform at Cowen
CVO Taken private
/

+

12/13/21 UBS
Cenveo initiated with a Neutral at UBS
DCBO Docebo
$49.33 /

+0.66 (+1.36%)

03/11/22 Canaccord
Docebo price target lowered to $65 from $80 at Canaccord
02/01/22 Canaccord
Docebo price target lowered to $80 from $95 at Canaccord
01/10/22 CIBC
Docebo price target lowered to C$102 from C$125 at CIBC
12/02/21 Stifel
Docebo initiated with a Buy at Stifel
DOC Physicians Realty Trust
$17.92 /

+0.29 (+1.64%)

02/28/22 BMO Capital
BMO can't rule out topping bid for Healthcare Trust
02/01/22 Credit Suisse
Physicians Realty Trust initiated with a Neutral at Credit Suisse
01/07/22 BMO Capital
Physicians Realty Trust downgraded to Market Perform from Outperform at BMO Capital
10/07/21 BMO Capital
Healthcare Trust price target raised to $35 from $32.50 at BMO Capital
DSG Diamond S Shipping
/

+

ECOM ChannelAdvisor
$16.42 /

+0.57 (+3.60%)

02/11/22 Needham
ChannelAdvisor price target lowered to $26 from $35 at Needham
02/02/22 B. Riley
ChannelAdvisor price target lowered to $32 from $38 at B. Riley
12/29/21 Baird
Baird announces three new top internet stock picks for 2022
09/20/21 Needham
ChannelAdvisor price target raised to $35 from $31 at Needham
EQ Equillium
$3.01 /

-0.265 (-8.09%)

03/24/22 H.C. Wainwright
Equillium price target raised to $15 from $12 at H.C. Wainwright
02/16/22 Stifel
Equillium's Bioniz acquisition bolsters itolizumab, says Stifel
01/12/22 Stifel
Equillium 'could be upside biased' into lupus nephritis data, says Stifel
10/29/21 Stifel
Equillium resumed with a Buy at Stifel
FORA Forian
$6.48 /

+0.34 (+5.54%)

PVT Pivotal Acquisition
/

+

QFOR Quadrant 4 System
/

+

REAL RealReal
$7.85 /

-0.01 (-0.13%)

03/22/22 UBS
RealReal price target lowered to $9 from $17 at UBS
03/17/22 Jefferies
RealReal initiated with a Buy at Jefferies
03/17/22 Jefferies
RealReal initiated with a Buy at Jefferies
02/24/22 Wedbush
RealReal price target lowered to $14 from $21 at Wedbush
REAL RealReal
$7.85 /

-0.01 (-0.13%)

EQ Equillium
$3.01 /

-0.265 (-8.09%)

ECOM ChannelAdvisor
$16.42 /

+0.57 (+3.60%)

DOC Physicians Realty Trust
$17.92 /

+0.29 (+1.64%)

DCBO Docebo
$49.33 /

+0.66 (+1.36%)

CTS CTS Corporation
$35.60 /

-0.55 (-1.52%)

CLS Celestica
$12.17 /

-0.1 (-0.81%)

BLD TopBuild
$192.69 /

+1.685 (+0.88%)

ABST Absolute Software
$8.34 /

-0.06 (-0.71%)

REAL RealReal
$7.85 /

-0.01 (-0.13%)

REAL RealReal
$7.85 /

-0.01 (-0.13%)

ECOM ChannelAdvisor
$16.42 /

+0.57 (+3.60%)

CLS Celestica
$12.17 /

-0.1 (-0.81%)

REAL RealReal
$7.85 /

-0.01 (-0.13%)

DOC Physicians Realty Trust
$17.92 /

+0.29 (+1.64%)

Conference/Events
Canaccord Genuity to hold a virtual conference » 17:12
03/28/22
03/28
17:12
03/28/22
17:12
ABST

Absolute Software

$8.34 /

-0.06 (-0.71%)

, AIF

Acceptance Insurance Group

$13.92 /

+0.005 (+0.04%)

, AT

Atlantic Power

$3.03 /

+ (+0.00%)

, BLD

TopBuild

$192.69 /

+1.685 (+0.88%)

, CLS

Celestica

$12.17 /

-0.1 (-0.81%)

, CTS

CTS Corporation

$35.60 /

-0.55 (-1.52%)

, CVO

Taken private

/

+

, DCBO

Docebo

$49.33 /

+0.66 (+1.36%)

, DOC

Physicians Realty Trust

$17.92 /

+0.29 (+1.64%)

, DSG

Diamond S Shipping

/

+

, ECOM

ChannelAdvisor

$16.42 /

+0.57 (+3.60%)

, EQ

Equillium

$3.01 /

-0.265 (-8.09%)

, FORA

Forian

$6.48 /

+0.34 (+5.54%)

, PVT

Pivotal Acquisition

/

+

, QFOR

Quadrant 4 System

/

+

, REAL

RealReal

$7.85 /

-0.01 (-0.13%)

Tech 2022: Themes in a…

Tech 2022: Themes in a Stock Picker's Market to be held on March 29.Webcast Link

ShowHide Related Items >><<
REAL RealReal
$7.85 /

-0.01 (-0.13%)

FORA Forian
$6.48 /

+0.34 (+5.54%)

EQ Equillium
$3.01 /

-0.265 (-8.09%)

DOC Physicians Realty Trust
$17.92 /

+0.29 (+1.64%)

DCBO Docebo
$49.33 /

+0.66 (+1.36%)

CTS CTS Corporation
$35.60 /

-0.55 (-1.52%)

CLS Celestica
$12.17 /

-0.1 (-0.81%)

BLD TopBuild
$192.69 /

+1.685 (+0.88%)

ABST Absolute Software
$8.34 /

-0.06 (-0.71%)

ABST Absolute Software
$8.34 /

-0.06 (-0.71%)

02/09/22 BMO Capital
Absolute Software price target lowered to C$14 from C$18.50 at BMO Capital
02/09/22 TD Securities
TD Securities upgrades Absolute Software to Buy after 'another' beat and raise
02/09/22 TD Securities
Absolute Software upgraded to Buy from Hold at TD Securities
08/11/21 BMO Capital
Absolute Software price target lowered to C$18.50 from C$20 at BMO Capital
AIF Acceptance Insurance Group
$13.92 /

+0.005 (+0.04%)

AT Atlantic Power
$3.03 /

+ (+0.00%)

BLD TopBuild
$192.69 /

+1.685 (+0.88%)

01/19/22 KeyBanc
TopBuild downgraded to Sector Weight from Overweight at KeyBanc
12/23/21
Fly Intel: Top five analyst upgrades
12/23/21 Zelman
TopBuild upgraded to Buy from Hold at Zelman
12/03/21
Fly Intel: Top five analyst downgrades
CLS Celestica
$12.17 /

-0.1 (-0.81%)

01/28/22 Canaccord
Celestica price target raised to $13.50 from $12 at Canaccord
09/23/21 Citi
Celestica price target raised to $8.50 from $8 at Citi
05/25/21 Stifel
Plexus warning may be signal that supply constraints will worsen, says Stifel
CTS CTS Corporation
$35.60 /

-0.55 (-1.52%)

01/31/22 Sidoti
CTS Corporation upgraded to Buy from Neutral at Sidoti
10/14/21 Cowen
CTS downgraded to Market Perform amid rising input costs at Cowen
10/14/21 Cowen
CTS Corporation downgraded to Market Perform from Outperform at Cowen
CVO Taken private
/

+

12/13/21 UBS
Cenveo initiated with a Neutral at UBS
DCBO Docebo
$49.33 /

+0.66 (+1.36%)

03/11/22 Canaccord
Docebo price target lowered to $65 from $80 at Canaccord
02/01/22 Canaccord
Docebo price target lowered to $80 from $95 at Canaccord
01/10/22 CIBC
Docebo price target lowered to C$102 from C$125 at CIBC
12/02/21 Stifel
Docebo initiated with a Buy at Stifel
DOC Physicians Realty Trust
$17.92 /

+0.29 (+1.64%)

02/28/22 BMO Capital
BMO can't rule out topping bid for Healthcare Trust
02/01/22 Credit Suisse
Physicians Realty Trust initiated with a Neutral at Credit Suisse
01/07/22 BMO Capital
Physicians Realty Trust downgraded to Market Perform from Outperform at BMO Capital
10/07/21 BMO Capital
Healthcare Trust price target raised to $35 from $32.50 at BMO Capital
DSG Diamond S Shipping
/

+

ECOM ChannelAdvisor
$16.42 /

+0.57 (+3.60%)

02/11/22 Needham
ChannelAdvisor price target lowered to $26 from $35 at Needham
02/02/22 B. Riley
ChannelAdvisor price target lowered to $32 from $38 at B. Riley
12/29/21 Baird
Baird announces three new top internet stock picks for 2022
09/20/21 Needham
ChannelAdvisor price target raised to $35 from $31 at Needham
EQ Equillium
$3.01 /

-0.265 (-8.09%)

03/24/22 H.C. Wainwright
Equillium price target raised to $15 from $12 at H.C. Wainwright
02/16/22 Stifel
Equillium's Bioniz acquisition bolsters itolizumab, says Stifel
01/12/22 Stifel
Equillium 'could be upside biased' into lupus nephritis data, says Stifel
10/29/21 Stifel
Equillium resumed with a Buy at Stifel
FORA Forian
$6.48 /

+0.34 (+5.54%)

PVT Pivotal Acquisition
/

+

QFOR Quadrant 4 System
/

+

REAL RealReal
$7.85 /

-0.01 (-0.13%)

03/22/22 UBS
RealReal price target lowered to $9 from $17 at UBS
03/17/22 Jefferies
RealReal initiated with a Buy at Jefferies
03/17/22 Jefferies
RealReal initiated with a Buy at Jefferies
02/24/22 Wedbush
RealReal price target lowered to $14 from $21 at Wedbush
REAL RealReal
$7.85 /

-0.01 (-0.13%)

EQ Equillium
$3.01 /

-0.265 (-8.09%)

ECOM ChannelAdvisor
$16.42 /

+0.57 (+3.60%)

DOC Physicians Realty Trust
$17.92 /

+0.29 (+1.64%)

DCBO Docebo
$49.33 /

+0.66 (+1.36%)

CTS CTS Corporation
$35.60 /

-0.55 (-1.52%)

CLS Celestica
$12.17 /

-0.1 (-0.81%)

BLD TopBuild
$192.69 /

+1.685 (+0.88%)

ABST Absolute Software
$8.34 /

-0.06 (-0.71%)

REAL RealReal
$7.85 /

-0.01 (-0.13%)

REAL RealReal
$7.85 /

-0.01 (-0.13%)

ECOM ChannelAdvisor
$16.42 /

+0.57 (+3.60%)

CLS Celestica
$12.17 /

-0.1 (-0.81%)

REAL RealReal
$7.85 /

-0.01 (-0.13%)

DOC Physicians Realty Trust
$17.92 /

+0.29 (+1.64%)

Recommendations
Equillium price target raised to $15 from $12 at H.C. Wainwright » 06:20
03/24/22
03/24
06:20
03/24/22
06:20
EQ

Equillium

$3.28 /

-0.02 (-0.61%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Equillium to $15 from $12 and keeps a Buy rating on the shares. The company's purchase of Bioniz expands its portfolio by adding two clinical-stage programs, Selvaraju tells investors in a research note. The analyst assigns a 30% probability of approval for EQ101 and a 20% probability of approval for EQ102.

ShowHide Related Items >><<
EQ Equillium
$3.28 /

-0.02 (-0.61%)

EQ Equillium
$3.28 /

-0.02 (-0.61%)

02/16/22 Stifel
Equillium's Bioniz acquisition bolsters itolizumab, says Stifel
01/12/22 Stifel
Equillium 'could be upside biased' into lupus nephritis data, says Stifel
10/29/21 Stifel
Equillium resumed with a Buy at Stifel
09/15/21
Fly Intel: Top five analyst initiations
EQ Equillium
$3.28 /

-0.02 (-0.61%)

Earnings
Equillium reports Q4 EPS (36c), consensus (34c) » 16:01
03/23/22
03/23
16:01
03/23/22
16:01
EQ

Equillium

$3.29 /

-0.01 (-0.30%)

"I'm proud of…

"I'm proud of our team and the progress we have made since the beginning of last year," said Bruce Steel, chief executive officer at Equillium. "In that short time, we have announced data from multiple clinical studies, strengthened our balance sheet with a direct investment from Decheng Capital, added two experienced members to our board of directors, and most recently completed the acquisition of Bioniz Therapeutics. Perhaps most exciting is what is still to come, as this acquisition expands our pipeline of first-in-class therapeutic candidates that have the potential to improve patient care and adds significantly to our future operational milestones and pending data catalysts."

ShowHide Related Items >><<
EQ Equillium
$3.29 /

-0.01 (-0.30%)

EQ Equillium
$3.29 /

-0.01 (-0.30%)

02/16/22 Stifel
Equillium's Bioniz acquisition bolsters itolizumab, says Stifel
01/12/22 Stifel
Equillium 'could be upside biased' into lupus nephritis data, says Stifel
10/29/21 Stifel
Equillium resumed with a Buy at Stifel
09/15/21
Fly Intel: Top five analyst initiations
EQ Equillium
$3.29 /

-0.01 (-0.30%)

Hot Stocks
Equillium initiates EQUATOR study » 08:05
03/04/22
03/04
08:05
03/04/22
08:05
EQ

Equillium

$3.47 /

-0.07 (-1.98%)

Equillium announced the…

Equillium announced the initiation of the EQUATOR study, a pivotal Phase 3 clinical study of itolizumab in patients with acute graft-versus-host disease, or aGVHD. The randomized, double-blind study will assess the efficacy and safety of itolizumab versus placebo as a first-line therapy for aGVHD in combination with corticosteroids. The primary objective of the study is to achieve early disease response, with key secondary objectives to evaluate durability of response, corticosteroid use, survival outcomes, and chronic GVHD incidence. The primary endpoint assessment is complete response, or CR, rate at Day 29, with key secondary endpoints of overall response rate (ORR) at Day 29 and durability of CR rate from Day 29 through Day 99.

ShowHide Related Items >><<
EQ Equillium
$3.47 /

-0.07 (-1.98%)

EQ Equillium
$3.47 /

-0.07 (-1.98%)

02/16/22 Stifel
Equillium's Bioniz acquisition bolsters itolizumab, says Stifel
01/12/22 Stifel
Equillium 'could be upside biased' into lupus nephritis data, says Stifel
10/29/21 Stifel
Equillium resumed with a Buy at Stifel
09/15/21
Fly Intel: Top five analyst initiations
EQ Equillium
$3.47 /

-0.07 (-1.98%)

Conference/Events
SVB Leerink to hold a virtual conference » 04:55
02/18/22
02/18
04:55
02/18/22
04:55
ACCD

Accolade

$19.27 /

-1.99 (-9.36%)

, BLUE

Bluebird Bio

$6.18 /

-0.305 (-4.71%)

, CCXI

ChemoCentryx

$30.43 /

-1.1 (-3.49%)

, DNAY

Codex DNA

$9.85 /

-0.29 (-2.86%)

, EW

Edwards Lifesciences

$106.90 /

-3.76 (-3.40%)

, FIXX

Homology Medicines

$3.88 /

-0.135 (-3.37%)

, GRAY

Graybug Vision

$1.24 /

-0.07 (-5.34%)

, HCA

HCA Healthcare

$250.76 /

-1.32 (-0.52%)

, IMTX

Immatics

$8.81 /

-0.245 (-2.71%)

, JNJ

Johnson & Johnson

$165.13 /

-1.01 (-0.61%)

, KALV

KalVista

$15.67 /

-0.26 (-1.63%)

, LVTX

Lava Therapeutics

$4.84 /

-0.025 (-0.51%)

, MD

Mednax

$24.20 /

-1.57 (-6.09%)

, NAUT

Nautilus Biotechnology

$3.84 /

-0.18 (-4.48%)

, OM

Outset Medical

$38.91 /

+4.57 (+13.31%)

, PINC

Premier

$36.13 /

-0.45 (-1.23%)

, QURE

uniQure

$16.31 /

-0.78 (-4.56%)

, RAIN

Rain Therapeutics

$6.95 /

-0.85 (-10.90%)

, SBTX

Silverback Therapeutics

$3.83 /

-0.36 (-8.59%)

, SPRB

Spruce Biosciences

$2.18 /

-0.14 (-6.03%)

, TNGX

Tango Therapeutics

$8.89 /

-0.05 (-0.56%)

, UTRS

Minerva Surgical

$5.34 /

-0.02 (-0.37%)

, ZYNE

Zynerba

$2.57 /

-0.15 (-5.51%)

, ADAG

Adagene

$6.52 /

-0.46 (-6.59%)

, BEAM

Beam Therapeutics

$68.96 /

-4.86 (-6.58%)

, CALA

Calithera Biosciences

/

+

, DICE

Dice Therapeutics

$16.10 /

-0.38 (-2.31%)

, EQ

Equillium

$4.08 /

-0.05 (-1.21%)

, FULC

Fulcrum Therapeutics

$10.26 /

-0.27 (-2.56%)

, MIRM

Mirum Pharmaceuticals

$22.96 /

+0.24 (+1.06%)

, NEO

NeoGenomics

$20.37 /

-1.7 (-7.70%)

, OPRX

OptimizeRx

$45.03 /

-3.9 (-7.97%)

, PACB

Pacific Biosciences

$11.03 /

-0.855 (-7.19%)

, QTRX

Quanterix

$28.48 /

-3.83 (-11.85%)

, RAPT

Rapt Therapeutics

$20.68 /

-1.31 (-5.96%)

, RHHBY

Roche

$46.67 /

-0.9 (-1.89%)

, TCRR

TCR2 Therapeutics

$2.91 /

-0.095 (-3.17%)

, VINC

Vincerx Pharma

$6.00 /

-0.28 (-4.46%)

, WVE

Wave Life Sciences

$3.02 /

+0.11 (+3.78%)

, XENE

Xenon Pharmaceuticals

$31.23 /

-1.835 (-5.55%)

, ZNTL

Zentalis

$49.59 /

-1.99 (-3.86%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference to be held on February 14-18.

ShowHide Related Items >><<
ZYNE Zynerba
$2.57 /

-0.15 (-5.51%)

ZNTL Zentalis
$49.59 /

-1.99 (-3.86%)

XENE Xenon Pharmaceuticals
$31.23 /

-1.835 (-5.55%)

WVE Wave Life Sciences
$3.02 /

+0.11 (+3.78%)

VINC Vincerx Pharma
$6.00 /

-0.28 (-4.46%)

UTRS Minerva Surgical
$5.34 /

-0.02 (-0.37%)

TNGX Tango Therapeutics
$8.89 /

-0.05 (-0.56%)

TCRR TCR2 Therapeutics
$2.91 /

-0.095 (-3.17%)

SPRB Spruce Biosciences
$2.18 /

-0.14 (-6.03%)

SBTX Silverback Therapeutics
$3.83 /

-0.36 (-8.59%)

RHHBY Roche
$46.67 /

-0.9 (-1.89%)

RAPT Rapt Therapeutics
$20.68 /

-1.31 (-5.96%)

RAIN Rain Therapeutics
$6.95 /

-0.85 (-10.90%)

QURE uniQure
$16.31 /

-0.78 (-4.56%)

QTRX Quanterix
$28.48 /

-3.83 (-11.85%)

PINC Premier
$36.13 /

-0.45 (-1.23%)

PACB Pacific Biosciences
$11.03 /

-0.855 (-7.19%)

OPRX OptimizeRx
$45.03 /

-3.9 (-7.97%)

OM Outset Medical
$38.91 /

+4.57 (+13.31%)

NEO NeoGenomics
$20.37 /

-1.7 (-7.70%)

NAUT Nautilus Biotechnology
$3.84 /

-0.18 (-4.48%)

MIRM Mirum Pharmaceuticals
$22.96 /

+0.24 (+1.06%)

MD Mednax
$24.20 /

-1.57 (-6.09%)

LVTX Lava Therapeutics
$4.84 /

-0.025 (-0.51%)

KALV KalVista
$15.67 /

-0.26 (-1.63%)

JNJ Johnson & Johnson
$165.13 /

-1.01 (-0.61%)

IMTX Immatics
$8.81 /

-0.245 (-2.71%)

HCA HCA Healthcare
$250.76 /

-1.32 (-0.52%)

GRAY Graybug Vision
$1.24 /

-0.07 (-5.34%)

FULC Fulcrum Therapeutics
$10.26 /

-0.27 (-2.56%)

FIXX Homology Medicines
$3.88 /

-0.135 (-3.37%)

EW Edwards Lifesciences
$106.90 /

-3.76 (-3.40%)

EQ Equillium
$4.08 /

-0.05 (-1.21%)

DNAY Codex DNA
$9.85 /

-0.29 (-2.86%)

DICE Dice Therapeutics
$16.10 /

-0.38 (-2.31%)

CCXI ChemoCentryx
$30.43 /

-1.1 (-3.49%)

CALA Calithera Biosciences
/

+

BLUE Bluebird Bio
$6.18 /

-0.305 (-4.71%)

BEAM Beam Therapeutics
$68.96 /

-4.86 (-6.58%)

ADAG Adagene
$6.52 /

-0.46 (-6.59%)

ACCD Accolade
$19.27 /

-1.99 (-9.36%)

ACCD Accolade
$19.27 /

-1.99 (-9.36%)

02/11/22 Goldman Sachs
Accolade initiated with a Buy at Goldman Sachs
01/11/22 BTIG
Accolade price target lowered to $35 from $60 at BTIG
01/11/22 Stifel
Accolade price target lowered to $34 from $40 at Stifel
01/11/22 Canaccord
Accolade price target lowered to $34 from $52 at Canaccord
BLUE Bluebird Bio
$6.18 /

-0.305 (-4.71%)

01/05/22 Wells Fargo
Avrobio price target lowered to $8 from $36 at Wells Fargo
12/06/21 Cowen
Cowen starts Crispr at Market Perform as applications 'need maturing'
11/12/21 BMO Capital
Bluebird Bio price target lowered to $13 from $21 at BMO Capital
11/08/21 Canaccord
2seventy Bio initiated with a Buy at Canaccord
CCXI ChemoCentryx
$30.43 /

-1.1 (-3.49%)

11/15/21 Raymond James
InflaRx's ANCA vasculitis data 'solid,' says Raymond James
11/10/21 Raymond James
ChemoCentryx price target raised to $110 from $107 at Raymond James
10/11/21 JPMorgan
ChemoCentryx upgraded to Neutral from Underweight at JPMorgan
10/11/21 SVB Securities
ChemoCentryx upgraded to Outperform from Market Perform at SVB Leerink
DNAY Codex DNA
$9.85 /

-0.29 (-2.86%)

12/30/21 KeyBanc
Pfizer deal provides key validation of Codex DNA's technology, says KeyBanc
10/14/21 Cowen
Codex DNA coverage transferred at Cowen
07/13/21 Cowen
Cowen starts 'promising' Codex DNA at Outperform
07/13/21 Jefferies
Jefferies starts 'discounted' Codex DNA at Buy with $23 price target
EW Edwards Lifesciences
$106.90 /

-3.76 (-3.40%)

01/27/22 Raymond James
Edwards Lifesciences price target lowered to $126 from $134 at Raymond James
01/27/22 Piper Sandler
Edwards Lifesciences price target lowered to $125 from $133 at Piper Sandler
01/07/22 Credit Suisse
Edwards Lifesciences price target raised to $144 from $131 at Credit Suisse
01/03/22 JPMorgan
JPMorgan says own these medical device stocks into next week's conference
FIXX Homology Medicines
$3.88 /

-0.135 (-3.37%)

09/07/21 Oppenheimer
BioMarin clinical hold has little read through to Homology, says Oppenheimer
05/18/21 Canaccord
Homology Medicines price target lowered to $19 from $37 at Canaccord
05/07/21 Oppenheimer
Homology Medicines price target lowered to $24 from $27 at Oppenheimer
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
GRAY Graybug Vision
$1.24 /

-0.07 (-5.34%)

12/15/21 Wedbush
Graybug Vision assumed with a Neutral, $3 target at Wedbush
12/15/21 Wedbush
Graybug Vision assumed with a Neutral at Wedbush
05/13/21
Fly Intel: Top five analyst downgrades
05/13/21 Cantor Fitzgerald
Graybug Vision price target lowered to $6 from $14 at Cantor Fitzgerald
HCA HCA Healthcare
$250.76 /

-1.32 (-0.52%)

02/07/22 BofA
BOFA adds Zoetis and Microsoft to best ideas list, removes two
01/31/22 BMO Capital
HCA Healthcare price target lowered to $250 from $275 at BMO Capital
01/31/22 Citi
HCA Healthcare price target lowered to $277 from $306 at Citi
01/28/22 Cowen
HCA Healthcare price target lowered to $265 from $302 at Cowen
IMTX Immatics
$8.81 /

-0.245 (-2.71%)

12/14/21 SVB Securities
SVB Leerink positive on Bristol-Myers deal, ups Immatics price target to $32
12/14/21 SVB Securities
Immatics price target raised to $32 from $28 at SVB Leerink
03/17/21 Chardan
Immatics' early TCR platform activity signals 'notable,' says Chardan
03/17/21 SVB Securities
Immatics price target raised to $26 from $17 at SVB Leerink
JNJ Johnson & Johnson
$165.13 /

-1.01 (-0.61%)

01/26/22 Raymond James
Johnson & Johnson price target raised to $185 from $178 at Raymond James
01/25/22 Citi
Johnson & Johnson quarter reflected 'resilience,' says Citi
12/29/21 Credit Suisse
Credit Suisse reiterates Outperform on J&J as trends point to pharma upside
12/17/21
Fly Intel: Top five analyst initiations
KALV KalVista
$15.67 /

-0.26 (-1.63%)

11/10/21 Roth Capital
KalVista FDA meeting feedback 'quite positive,' says Roth Capital
08/23/21 Roth Capital
KalVista could take 'substantial' share of HAE market, says Roth Capital
04/20/21 Roth Capital
KalVista selloff seems overdone after clinical hold, says Roth Capital
LVTX Lava Therapeutics
$4.84 /

-0.025 (-0.51%)

04/19/21 SVB Securities
SVB Leerink bullish on Lava Therapeutics, initiates with an Outperform
04/19/21 JPMorgan
Lava Therapeutics initiated with an Overweight at JPMorgan
04/19/21 Jefferies
Lava Therapeutics initiated with a Buy at Jefferies
04/19/21 SVB Securities
Lava Therapeutics initiated with an Outperform at SVB Leerink
MD Mednax
$24.20 /

-1.57 (-6.09%)

12/20/21 Mizuho
Mednax price target lowered to $28 from $32 at Mizuho
11/01/21 BMO Capital
Mednax price target lowered to $31 from $37 at BMO Capital
10/13/21 Truist
Mednax price target lowered to $31 from $37 at Truist
09/27/21 SVB Securities
SVB Leerink starts Mednax at Market Perform with $29 price target
NAUT Nautilus Biotechnology
$3.84 /

-0.18 (-4.48%)

01/06/22 Morgan Stanley
Nautilus Biotechnology initiated with an Equal Weight at Morgan Stanley
11/02/21 Cowen
Cowen starts Nautilus Biotechnology with Outperform, Proteomics potential seen
11/02/21 Cowen
Nautilus Biotechnology initiated with an Outperform at Cowen
08/03/21 Goldman Sachs
Nautilus Biotechnology initiated with a Neutral at Goldman Sachs
OM Outset Medical
$38.91 /

+4.57 (+13.31%)

02/17/22 Morgan Stanley
Outset Medical upgraded at Morgan Stanley on inflecting Home opportunity
02/17/22 Cowen
Outset Medical price target lowered to $60 from $70 at Cowen
08/27/21 BofA
Outset Medical remains a 'top idea' at BofA
08/23/21 Cowen
CMS rule comments show clear support for Outset's Tablo, says Cowen
PINC Premier
$36.13 /

-0.45 (-1.23%)

11/18/21 Barclays
Premier price target raised to $36 from $34 at Barclays
11/03/21 Piper Sandler
Premier price target raised to $39 from $31 at Piper Sandler
05/28/21
Fly Intel: Top five analyst downgrades
05/28/21 Barclays
Barclays double downgrades Premier with multiple expansion less likely
QURE uniQure
$16.31 /

-0.78 (-4.56%)

12/16/21 Raymond James
uniQure downgraded to Outperform at Raymond James after Huntington's data update
12/16/21 Raymond James
uniQure downgraded to Outperform from Strong Buy at Raymond James
12/16/21 H.C. Wainwright
uniQure selloff on Huntington's data 'overdone,' says H.C. Wainwright
10/27/21 William Blair
uniQure initiated with an Outperform at William Blair
RAIN Rain Therapeutics
$6.95 /

-0.85 (-10.90%)

01/03/22 Guggenheim
Rain Therapeutics price target lowered to $20 from $26 at Guggenheim
11/10/21 Piper Sandler
Rain Therapeutics price target raised to $26 from $25 at Piper Sandler
09/14/21
Fly Intel: Top five analyst downgrades
09/14/21 Goldman Sachs
Rain Therapeutics assumed with Neutral from Buy at Goldman Sachs
SBTX Silverback Therapeutics
$3.83 /

-0.36 (-8.59%)

07/07/21 H.C. Wainwright
Silverback strikes pact with Regeneron for Libtayo, says H.C. Wainwright
05/27/21
Fly Intel: Top five analyst initiations
05/27/21 JonesTrading
Silverback Therapeutics initiated with a Buy at JonesTrading
03/30/21 Goldman Sachs
Silverback price target raised to $48 from $43 at Goldman Sachs
SPRB Spruce Biosciences
$2.18 /

-0.14 (-6.03%)

12/16/21 Oppenheimer
Oppenheimer starts 'quality biotech name' Spruce Biosciences at Outperform
12/16/21 Oppenheimer
Spruce Biosciences initiated with an Outperform at Oppenheimer
12/10/21 Benchmark
Spruce Biosciences initiated with a Speculative Buy at Benchmark
11/23/21 Cowen
Spruce Biosciences downgraded to Market Perform from Outperform at Cowen
TNGX Tango Therapeutics
$8.89 /

-0.05 (-0.56%)

09/20/21 SVB Securities
SVB Leerink bullish on Tango Therapeutics, initiates with an Outperform
09/20/21 SVB Securities
Tango Therapeutics initiated with an Outperform at SVB Leerink
09/07/21
Fly Intel: Top five analyst initiations
09/07/21 Wedbush
Tango Therapeutics initiated with an Outperform at Wedbush
UTRS Minerva Surgical
$5.34 /

-0.02 (-0.37%)

01/14/22 Piper Sandler
Piper tells small cap investors to buy basket of recent med tech IPOs
12/03/21 Piper Sandler
Piper 'strongly' encourages buying Minerva shares after Q3 print
11/16/21
Fly Intel: Top five analyst initiations
11/16/21 SVB Securities
SVB Leerink bullish on Minerva Surgical, initiates with an Outperform
ZYNE Zynerba
$2.57 /

-0.15 (-5.51%)

06/25/21 Alliance Global Partners
Cannabis selloff brings buying opportunities, says Alliance Global
05/06/21 Cantor Fitzgerald
Zynerba price target raised to $8 from $6 at Cantor Fitzgerald
03/29/21 Stifel
Stifel says New York adult use cannabis market represents $5B opportunity
03/10/21 Roth Capital
Zynerba price target lowered to $7.25 from $8.00 at Roth Capital
ADAG Adagene
$6.52 /

-0.46 (-6.59%)

02/01/22 Morgan Stanley
Adagene price target lowered to $15 from $27 at Morgan Stanley
06/25/21
Fly Intel: Top five analyst initiations
06/25/21 China Renaissance
Adagene initiated with a Buy, $40.57 target at China Renaissance
06/24/21 China Renaissance
Adagene initiated with a Buy at China Renaissance
BEAM Beam Therapeutics
$68.96 /

-4.86 (-6.58%)

01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 Guggenheim
Guggenheim starts Beam Therapeutics with a Buy rating, $130 price target
01/05/22 Guggenheim
Beam Therapeutics initiated with a Buy at Guggenheim
10/19/21 SVB Securities
Beam Therapeutics initiated with an Outperform at SVB Leerink
CALA Calithera Biosciences
/

+

01/31/22 Ladenburg
Calithera initiated with Buy, $4 price target at Ladenburg
01/31/22 Ladenburg
Calithera Biosciences initiated with a Buy at Ladenburg
01/20/22 SVB Securities
Calithera Biosciences upgraded to Outperform from Market Perform at SVB Leerink
11/08/21 William Blair
Calithera downgraded to Market Perform at William Blair after trial miss
DICE Dice Therapeutics
$16.10 /

-0.38 (-2.31%)

10/11/21 SVB Securities
Dice Therapeutics initiated with an Outperform at SVB Leerink
10/11/21 Evercore ISI
Evercore ISI starts Dice Therapeutics at Outperform, sees 120% upside
10/11/21 BofA
Dice Therapeutics initiated with a Buy at BofA
10/11/21 Evercore ISI
Dice Therapeutics initiated with an Outperform at Evercore ISI
EQ Equillium
$4.08 /

-0.05 (-1.21%)

02/16/22 Stifel
Equillium's Bioniz acquisition bolsters itolizumab, says Stifel
01/12/22 Stifel
Equillium 'could be upside biased' into lupus nephritis data, says Stifel
10/29/21 Stifel
Equillium resumed with a Buy at Stifel
09/15/21
Fly Intel: Top five analyst initiations
FULC Fulcrum Therapeutics
$10.26 /

-0.27 (-2.56%)

01/06/22 Stifel
Fulcrum pullback due to headline with 'inaccurate information,' says Stifel
08/17/21 Piper Sandler
Fulcrum Therapeutics price target raised to $46 from $20 at Piper Sandler
08/17/21 H.C. Wainwright
Fulcrum Therapeutics price target raised to $40 from $20 at H.C. Wainwright
08/11/21 Credit Suisse
Fulcrum Therapeutics price target raised to $30 from $20 at Credit Suisse
MIRM Mirum Pharmaceuticals
$22.96 /

+0.24 (+1.06%)

10/11/21 Piper Sandler
Mirum Pharmaceuticals remains undervalued despite catalysts, says Piper Sandler
09/30/21 H.C. Wainwright
Mirum Pharmaceuticals price target raised to $64 from $51 at H.C. Wainwright
09/30/21 Raymond James
Mirum Pharmaceuticals price target raised to $69 from $51 at Raymond James
09/30/21 Baird
Mirum Pharmaceuticals price target raised to $34 from $30 at Baird
NEO NeoGenomics
$20.37 /

-1.7 (-7.70%)

01/18/22 Stephens
NeoGenomics assumed with an Overweight at Stephens
12/16/21 Cowen
NeoGenomics initiated with an Outperform at Cowen
12/07/21 Needham
NeoGenomics price target lowered to $41 from $48 at Needham
11/05/21 Morgan Stanley
Morgan Stanley downgrades NeoGenomics, sees limited near-term upside
OPRX OptimizeRx
$45.03 /

-3.9 (-7.97%)

02/16/22 Lake Street
OptimizeRx price target lowered to $76 from $98 at Lake Street
01/24/22 William Blair
William Blair sees 'compelling' entry points for two healthcare tech names
12/27/21 B. Riley
B. Riley recommends LifeMD, OptimizeRx, Semler, Zynex into 2022
11/10/21 Roth Capital
OptimizeRx price target raised to $112 from $85 at Roth Capital
PACB Pacific Biosciences
$11.03 /

-0.855 (-7.19%)

02/16/22 Canaccord
Pacific Biosciences price target lowered to $40 from $45 at Canaccord
01/21/22 Cantor Fitzgerald
Pacific Biosciences assumed with an Overweight at Cantor Fitzgerald
01/11/22 Piper Sandler
Pacific Biosciences has new competitor in Illumina, says Piper Sandler
01/05/22 Piper Sandler
Pacific Biosciences assumed with a Neutral at Piper Sandler
QTRX Quanterix
$28.48 /

-3.83 (-11.85%)

10/14/21 Cowen
Quanterix coverage transferred at Cowen
06/04/21
Fly Intel: Top five analyst initiations
06/04/21 Goldman Sachs
Quanterix initiated with a Sell at Goldman Sachs
05/06/21 SVB Securities
Quanterix price target lowered to $70 from $85 at SVB Leerink
RAPT Rapt Therapeutics
$20.68 /

-1.31 (-5.96%)

12/09/21 JPMorgan
Rapt Therapeutics initiated with an Overweight at JPMorgan
11/16/21 Cantor Fitzgerald
Rapt Therapeutics price target lowered to $58 from $71 at Cantor Fitzgerald
08/12/21 SVB Securities
Rapt Therapeutics initiated with an Outperform at SVB Leerink
07/12/21 Roth Capital
Roth adds more 'SMID-cap' names to second half top picks
RHHBY Roche
$46.67 /

-0.9 (-1.89%)

02/11/22 H.C. Wainwright
Regeneron's Eylea data 'turns up heat' in wet AMD fight, says H.C. Wainwright
01/14/22 BofA
Biogen price target lowered to $245 from $275 at BofA
01/04/22 JPMorgan
Roche price target raised to CHF 390 from CHF 360 at JPMorgan
12/22/21 Citi
Roche resumed with a Buy at Citi
TCRR TCR2 Therapeutics
$2.91 /

-0.095 (-3.17%)

01/19/22 Goldman Sachs
TCR2 Therapeutics assumed with Neutral from Buy at Goldman Sachs
01/13/22 H.C. Wainwright
TCR2 Therapeutics price target lowered to $19 from $25 at H.C. Wainwright
11/29/21 Piper Sandler
TCR2 Therapeutics recent selloff brings buying opportunity, says Piper Sandler
11/18/21 Piper Sandler
TCR2 Therapeutics transferred with an Overweight at Piper Sandler
VINC Vincerx Pharma
$6.00 /

-0.28 (-4.46%)

01/14/22 H.C. Wainwright
Vincerx Pharma initiated with a Buy at H.C. Wainwright
12/23/21
Fly Intel: Top five analyst initiations
12/23/21 Cantor Fitzgerald
Vincerx Pharma initiated with an Overweight at Cantor Fitzgerald
12/23/21 Cantor Fitzgerald
Vincerx Pharma initiated with an Overweight at Cantor Fitzgerald
WVE Wave Life Sciences
$3.02 /

+0.11 (+3.78%)

05/19/21 Mizuho
Wave Life Sciences price target raised to $8 from $7 at Mizuho
03/30/21 Truist
Wave Life Sciences price target lowered to $17 from $27 at Truist
03/30/21 Mizuho
Wave Life Sciences price target lowered to $7 from $21 at Mizuho
03/30/21 RBC Capital
Wave Life Sciences price target lowered to $8 from $13 at RBC Capital
XENE Xenon Pharmaceuticals
$31.23 /

-1.835 (-5.55%)

11/11/21 SVB Securities
Xenon Pharmaceuticals price target raised to $40 from $34 at SVB Leerink
10/28/21 RBC Capital
Xenon Pharmaceuticals initiated with an Outperform at RBC Capital
10/06/21 Wedbush
Wedbush remains bullish on Xenon as financing gives firepower to advance XEN1101
10/04/21 Jefferies
Jefferies ups Xenon target to $50 after 'home run' epilepsy data
ZNTL Zentalis
$49.59 /

-1.99 (-3.86%)

11/11/21 H.C. Wainwright
Zentalis price target raised to $120 from $80 at H.C. Wainwright
10/28/21 SVB Securities
Zentalis price target raised to $84 from $64 at SVB Leerink
10/27/21 Wedbush
Zentalis price target raised to $89 from $65 at Wedbush
10/19/21 Morgan Stanley
Zentalis assumed with an Overweight at Morgan Stanley
ZYNE Zynerba
$2.57 /

-0.15 (-5.51%)

ZNTL Zentalis
$49.59 /

-1.99 (-3.86%)

XENE Xenon Pharmaceuticals
$31.23 /

-1.835 (-5.55%)

WVE Wave Life Sciences
$3.02 /

+0.11 (+3.78%)

VINC Vincerx Pharma
$6.00 /

-0.28 (-4.46%)

UTRS Minerva Surgical
$5.34 /

-0.02 (-0.37%)

TNGX Tango Therapeutics
$8.89 /

-0.05 (-0.56%)

TCRR TCR2 Therapeutics
$2.91 /

-0.095 (-3.17%)

SBTX Silverback Therapeutics
$3.83 /

-0.36 (-8.59%)

RHHBY Roche
$46.67 /

-0.9 (-1.89%)

RAIN Rain Therapeutics
$6.95 /

-0.85 (-10.90%)

QURE uniQure
$16.31 /

-0.78 (-4.56%)

QTRX Quanterix
$28.48 /

-3.83 (-11.85%)

PINC Premier
$36.13 /

-0.45 (-1.23%)

PACB Pacific Biosciences
$11.03 /

-0.855 (-7.19%)

OPRX OptimizeRx
$45.03 /

-3.9 (-7.97%)

OM Outset Medical
$38.91 /

+4.57 (+13.31%)

NAUT Nautilus Biotechnology
$3.84 /

-0.18 (-4.48%)

MIRM Mirum Pharmaceuticals
$22.96 /

+0.24 (+1.06%)

MD Mednax
$24.20 /

-1.57 (-6.09%)

LVTX Lava Therapeutics
$4.84 /

-0.025 (-0.51%)

KALV KalVista
$15.67 /

-0.26 (-1.63%)

JNJ Johnson & Johnson
$165.13 /

-1.01 (-0.61%)

IMTX Immatics
$8.81 /

-0.245 (-2.71%)

HCA HCA Healthcare
$250.76 /

-1.32 (-0.52%)

GRAY Graybug Vision
$1.24 /

-0.07 (-5.34%)

FULC Fulcrum Therapeutics
$10.26 /

-0.27 (-2.56%)

FIXX Homology Medicines
$3.88 /

-0.135 (-3.37%)

EW Edwards Lifesciences
$106.90 /

-3.76 (-3.40%)

EQ Equillium
$4.08 /

-0.05 (-1.21%)

DNAY Codex DNA
$9.85 /

-0.29 (-2.86%)

DICE Dice Therapeutics
$16.10 /

-0.38 (-2.31%)

CCXI ChemoCentryx
$30.43 /

-1.1 (-3.49%)

CALA Calithera Biosciences
/

+

BLUE Bluebird Bio
$6.18 /

-0.305 (-4.71%)

BEAM Beam Therapeutics
$68.96 /

-4.86 (-6.58%)

ADAG Adagene
$6.52 /

-0.46 (-6.59%)

ACCD Accolade
$19.27 /

-1.99 (-9.36%)

  • 22
    Oct
  • 06
    Oct
  • 15
    Sep
  • 12
    Aug
  • 29
    Jun
  • 16
    Jun
  • 18
    Jun
  • 23
    Apr
  • 09
    Apr
  • 07
    Apr
  • 25
    Mar
  • 10
    Mar
ZYNE Zynerba
$2.57 /

-0.15 (-5.51%)

RHHBY Roche
$46.67 /

-0.9 (-1.89%)

NEO NeoGenomics
$20.37 /

-1.7 (-7.70%)

JNJ Johnson & Johnson
$165.13 /

-1.01 (-0.61%)

ZYNE Zynerba
$2.57 /

-0.15 (-5.51%)

VINC Vincerx Pharma
$6.00 /

-0.28 (-4.46%)

UTRS Minerva Surgical
$5.34 /

-0.02 (-0.37%)

TCRR TCR2 Therapeutics
$2.91 /

-0.095 (-3.17%)

SPRB Spruce Biosciences
$2.18 /

-0.14 (-6.03%)

SBTX Silverback Therapeutics
$3.83 /

-0.36 (-8.59%)

RHHBY Roche
$46.67 /

-0.9 (-1.89%)

QURE uniQure
$16.31 /

-0.78 (-4.56%)

QTRX Quanterix
$28.48 /

-3.83 (-11.85%)

PACB Pacific Biosciences
$11.03 /

-0.855 (-7.19%)

OPRX OptimizeRx
$45.03 /

-3.9 (-7.97%)

OM Outset Medical
$38.91 /

+4.57 (+13.31%)

NEO NeoGenomics
$20.37 /

-1.7 (-7.70%)

JNJ Johnson & Johnson
$165.13 /

-1.01 (-0.61%)

HCA HCA Healthcare
$250.76 /

-1.32 (-0.52%)

EW Edwards Lifesciences
$106.90 /

-3.76 (-3.40%)

DNAY Codex DNA
$9.85 /

-0.29 (-2.86%)

DICE Dice Therapeutics
$16.10 /

-0.38 (-2.31%)

CCXI ChemoCentryx
$30.43 /

-1.1 (-3.49%)

BLUE Bluebird Bio
$6.18 /

-0.305 (-4.71%)

BEAM Beam Therapeutics
$68.96 /

-4.86 (-6.58%)

ACCD Accolade
$19.27 /

-1.99 (-9.36%)

PACB Pacific Biosciences
$11.03 /

-0.855 (-7.19%)

OM Outset Medical
$38.91 /

+4.57 (+13.31%)

MIRM Mirum Pharmaceuticals
$22.96 /

+0.24 (+1.06%)

JNJ Johnson & Johnson
$165.13 /

-1.01 (-0.61%)

EW Edwards Lifesciences
$106.90 /

-3.76 (-3.40%)

CCXI ChemoCentryx
$30.43 /

-1.1 (-3.49%)

BLUE Bluebird Bio
$6.18 /

-0.305 (-4.71%)

ACCD Accolade
$19.27 /

-1.99 (-9.36%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.